Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury

Biochemical and Biophysical Research Communications

Volumn 470, Issue 3, 2016, Pages 539-545

  Tanaka, Yuki ^a   Kume, Shinji ^a   Chin Kanasaki, Masami ^a   Araki, Hisazumi ^a   Araki, Shin Ichi ^a   Ugi, Satoshi ^a   Sugaya, Takeshi ^b   Uzu, Takashi ^a   Maegawa, Hiroshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Albuminuria; Diabetic nephropathy; DPP 4 inhibitors; Free fatty acid; Proximal tubular cell

Indexed keywords

ALBUMIN; ALOGLIPTIN; COLLAGEN TYPE 1; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FATTY ACID; FIBRONECTIN; GLUCOSE; INTERLEUKIN 6; LINAGLIPTIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; SITAGLIPTIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VILDAGLIPTIN; ALBUMINOID; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; FOOD INTAKE; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DAMAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL PROTECTION; DOSE RESPONSE; DRUG EFFECTS; INJURIES; METABOLISM; TREATMENT OUTCOME;

ALBUMINS; ANIMALS; APOPTOSIS; CELLS, CULTURED; CYTOPROTECTION; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; KIDNEY TUBULES, PROXIMAL; MALE; MICE; MICE, INBRED C57BL; TREATMENT OUTCOME;

EID: 84957428998     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.01.109     Document Type: Article

References (29)

1. C.V. Desouza, N. Gupta, and A. Patel Cardiometabolic effects of a new class of antidiabetic agents Clin. Ther. 37 2015 1178 1194
2. I. Kanazawa, K. Tanaka, and T. Sugimoto DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus Med. Sci. Monit. 20 2014 1662 1667
3. A.R. Aroor, J.R. Sowers, G. Jia, and V.G. DeMarco Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system Am. J. Physiol. Heart Circ. Physiol. 307 2014 H477 H492
4. S.G. Chrysant, and G.S. Chrysant Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors Am. J. Cardiol. 109 2012 1681 1685
5. W.J. Liu, S.H. Xie, Y.N. Liu, W. Kim, H.Y. Jin, S.K. Park, Y.M. Shao, and T.S. Park Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats J. Pharmacol. Exp. Ther. 340 2012 248 255
6. K. Kanasaki, S. Shi, M. Kanasaki, J. He, T. Nagai, Y. Nakamura, Y. Ishigaki, M. Kitada, S.P. Srivastava, and D. Koya Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen Diabetes 63 2014 2120 2131
7. M.L. Alter, I.M. Ott, K. von Websky, O. Tsuprykov, Y. Sharkovska, K. Krause-Relle, J. Raila, A. Henze, T. Klein, and B. Hocher DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy Kidney Blood Press Res. 36 2012 119 130
8. Y. Kirino, Y. Sato, T. Kamimoto, K. Kawazoe, K. Minakuchi, and Y. Nakahori Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats J. Endocrinol. 200 2009 53 61
9. C. Mega, E.T. de Lemos, H. Vala, R. Fernandes, J. Oliveira, F. Mascarenhas-Melo, F. Teixeira, and F. Reis Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat) Exp. Diabetes Res. 2011 2011 162092
10. C. Marques, C. Mega, A. Gonçalves, P. Rodrigues-Santos, E. Teixeira-Lemos, F. Teixeira, C. Fontes-Ribeiro, F. Reis, and R. Fernandes Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals Mediat. Inflamm. 2014 2014 538737
11. J. Vaghasiya, N. Sheth, Y. Bhalodia, and R. Manek Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes Regul. Pept. 166 2011 48 54
12. S. Nakashima, T. Matsui, M. Takeuchi, and S.I. Yamagishi Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis Horm. Metab. Res. 46 2014 717 721
13. Y. Sharkovska, C. Reichetzeder, M. Alter, O. Tsuprykov, S. Bachmann, T. Secher, T. Klein, and B. Hocher Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy J. Hypertens. 32 2014 2211 2223 discussion 2223
14. M. Haluzík, J. Frolík, and I. Rychlík Renal effects of DPP-4 inhibitors: a focus on microalbuminuria Int. J. Endocrinol. 2013 2013 895102
15. C. Ott, U. Raff, S. Schmidt, I. Kistner, S. Friedrich, P. Bramlage, J.M. Harazny, and R.E. Schmieder Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes Cardiovasc. Diabetol. 13 2014 19
16. P.H. Groop, M.E. Cooper, V. Perkovic, A. Emser, H.J. Woerle, and M. von Eynatten Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction Diabetes Care 36 2013 3460 3468
17. S. Kröller-Schön, M. Knorr, M. Hausding, M. Oelze, A. Schuff, R. Schell, S. Sudowe, A. Scholz, S. Daub, S. Karbach, S. Kossmann, T. Gori, P. Wenzel, E. Schulz, S. Grabbe, T. Klein, T. Münzel, and A. Daiber Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition Cardiovasc. Res. 96 2012 140 149
18. Y. Tanaka, S. Kume, S. Araki, K. Isshiki, M. Chin-Kanasaki, M. Sakaguchi, T. Sugimoto, D. Koya, M. Haneda, A. Kashiwagi, H. Maegawa, and T. Uzu Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis Kidney Int. 79 2011 871 882
19. M. Soumura, S. Kume, K. Isshiki, N. Takeda, S. Araki, Y. Tanaka, T. Sugimoto, M. Chin-Kanasaki, Y. Nishio, M. Haneda, D. Koya, A. Kashiwagi, H. Maegawa, and T. Uzu Oleate and eicosapentaenoic acid attenuate palmitate-induced inflammation and apoptosis in renal proximal tubular cell Biochem. Biophys. Res. Commun. 402 2010 265 271
20. N. Takeda, S. Kume, Y. Tanaka, Y. Morita, M. Chin-Kanasaki, H. Araki, K. Isshiki, S. Araki, M. Haneda, D. Koya, A. Kashiwagi, H. Maegawa, and T. Uzu Altered unfolded protein response is implicated in the age-related exacerbation of proteinuria-induced proximal tubular cell damage Am. J. Pathol. 183 2013 774 785
21. X. Yang, S. Kume, Y. Tanaka, K. Isshiki, S. Araki, M. Chin-Kanasaki, T. Sugimoto, D. Koya, M. Haneda, T. Sugaya, D. Li, P. Han, Y. Nishio, A. Kashiwagi, H. Maegawa, and T. Uzu GW501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice PLoS One 6 2011 e25271
22. A. Kamijo, K. Kimura, T. Sugaya, M. Yamanouchi, H. Hase, T. Kaneko, Y. Hirata, A. Goto, T. Fujita, and M. Omata Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage Kidney Int. 62 2002 1628 1637
23. M.E. Thomas, K.P. Harris, J. Walls, P.N. Furness, and N.J. Brunskill Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria Am. J. Physiol. Ren. Physiol. 283 2002 F640 F647
24. P.A. Sarafidis, and G.L. Bakris Protection of the kidney by thiazolidinediones: an assessment from bench to bedside Kidney Int. 70 2006 1223 1233
25. P.A. Sarafidis, P.C. Stafylas, P.I. Georgianos, A.N. Saratzis, and A.N. Lasaridis Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis Am. J. Kidney Dis. 55 2010 835 847
26. R. Kodera, K. Shikata, T. Takatsuka, K. Oda, S. Miyamoto, N. Kajitani, D. Hirota, T. Ono, H.K. Usui, and H. Makino Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes Biochem. Biophys. Res. Commun. 443 2014 828 833
27. J. Yang, J. Campitelli, G. Hu, Y. Lin, J. Luo, and C. Xue Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin Life Sci. 81 2007 272 279
28. H. Fuchs, R. Binder, and A. Greischel Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats Biopharm. Drug Dispos. 30 2009 229 240
29. A. Greischel, R. Binder, and J. Baierl The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats Drug Metab. Dispos. 38 2010 1443 1448